1. Aims and Scope
Turkish Endodontic Journal (TEJ) is the official scientific publication of Turkish Endodontic Society and open access, peer-reviewed international journal. TEJ is published three times per year (May, August, December). The authors are invited to submit original scientific articles, case reports, review articles regarding endodontology and dental traumatology. Letter to the Editor section is also available for authors to write a comment letter on a previously published article in the journal.
TEJ does not charge authors or authors’ institutions to submit, process or publish articles. There is no fee for extra pages or color images.
2. Editorial Policies and Ethical Considerations
The acceptance criteria for all articles are the article’s quality, originality and its significance to our readership. Except where otherwise stated, manuscripts are peer-reviewed by two anonymous reviewers and the Editor. The final decision is given by the Editorial Board, which reserves the right to refuse any material for publication.
Manuscripts should be written in a clear, concise, direct style. Editor-in-Chief or the Editorial Board reserves the right to change the format, grammar, or sentence structure of any part of the manuscript to comply with the guidelines to fit the standard format and journal style.
TEJ strictly adheres to the International Committee of Medical Journal Editors (ICMJE) standards to define the authorship qualifications. We recommend that an author should provide ALL of the following four criteria:
(1) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work;
(2) Drafting the work or revising it critically for important intellectual content;
(3) Final approval of the version to be published;
(4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Contributors who do not qualify as authors should be mentioned under ‘Acknowledgements’.
Authors should take collective responsibility for their work and the content of their publications. Corresponding author should submit Authors Contribution Form before proceeding with further submission and evaluation processes.
Declaration of Artificial Intelligence (AI)–Assisted Technology in Scientific Writing
At submission, authors should disclose whether they used artificial intelligence (AI)– assisted technologies (such as Large Language Models [LLMs], chatbots, or image creators) in the production of submitted work. Authors who use such technology should describe, in both the Title Page and the submitted work, how they used it. Authors who used AI technology to conduct the study should describe its use in the methods section in sufficient detail to enable replication to the approach, including the tool used, version, and prompts where applicable. Chatbots (such as ChatGPT) and AI assisted technologies should not be listed as an author or co-author nor cited because they cannot be responsible for the accuracy, integrity, and originality of the work, and these responsibilities are required for authorship. Therefore, humans are responsible for any submitted material that included the use of AI-assisted technologies. Authors should carefully review and edit the result because AI can generate authoritative-sounding output that can be incorrect, incomplete, or biased. Authors should be able to assert that there is no plagiarism in their paper, including in text and images produced by the AI. Humans must ensure there is appropriate attribution of all quoted material, including full citations.
Authors must declare any financial support or relationships that may pose a conflict of interest by disclosing any financial arrangements they have with a company whose product figures prominently in the submitted manuscript or with a company making a competing product, or any conflict relating to technology or methodology. The absence of any interest to disclose must also be stated.
All submissions should comply with the ICMJE Uniform requirements. Submission of checklists and flow charts of Preferred Reporting Items for Study Designs in Endodontics (PRIDE) requirements are mandatory before proceeding the article processing for case reports (PRICE), animal studies (PRIASE), randomised clinical trials (PRIRATE), laboratory studies (PRILE). Systematic reviews and meta analysis should comply with Transparent reporting of systematic reviews and meta-analysis (PRISMA). Observational studies should comply with Strengthening the reporting of observational studies in epidemiology (STROBE). Diagnostic accuracy studies should comply with Essential Items for Reporting Diagnostic Accuracy Studies (STARD). All relevant and required checklists and flow charts can be found at: https://turkishendodonticjournal.com/Forms
Disclaimer and Copyright
Submission of a manuscript implies that the work described has not been published before; that it is not under consideration for publication anywhere else entirely or partially, nor will it be submitted for consideration of publication anywhere else until a final publication decision concerning this manuscript has been made by the Editor(s) of the Journal; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities at the institute where the work has been carried out. The publisher cannot be held legally responsible should there be any compensation claims.
TEJ provides free access to and allows free download of its contents from the journal’s website (https://turkendodontidernegi.org/page.aspx?menu=53). Both anonymous or registered users can read and/or download articles for personal use. The material cannot be used for commercial purposes. The license does not give the user all of the permissions necessary for his/her intended use. For example, other rights such as publicity, privacy, or moral rights may limit how the material can be used.
Articles cannot be published elsewhere, in whole or in part, electronically or in print, without written permission from the Editor-in-Chief. The responsibility of the content(s) and/or opinion(s) provided in the articles which are published in the print and/or online versions of the journal, belong exclusively to their respective author(s). The publisher/editor/editorial board/reviewers cannot be held responsible for errors, scientific or otherwise, in the contents or any consequences arising from the use of the information contained therein. The opinions expressed in the articles published in this journal are purely those of their respective authors and in no way represent the opinions of the publisher/editor/editorial board/reviewers of the journal.
Publication ethics and avoiding allegations of plagiarism
Please refer to TEJ Publication Ethics and Publication Malpractice Statement. By submitting their manuscripts to TEJ, authors also accept that their manuscripts may be screened for signs of plagiarism using any means necessary and available; including, but not limited to, the use of plagiarism detection software.
Experimentation involving human subjects should be conducted in full accordance with the Helsinki Declaration of World Medical Association (http://www.wma.net/en/30publications/10policies/b3/index.html) and legal requirements of the country where the research had been carried out. The manuscript must include a statement indicating that informed consent was obtained from all participants. A statement confirming that the study has been reviewed and approved by an ethical or advisory board with the approval number and board name should also be included. The patient’s privacy should not be violated. Identifying information such as names, initials, hospital numbers, unnecessary details in photographs should be omitted from the submission. When detailed descriptions, photographs and/or videos of faces or identifiable body parts that might permit a patient to be identified must be included in the submission, authors must obtain written informed consent for its publication from the patient or his/her parent/guardian.
Experiments on laboratory animals must comply with the Guidelines of the European Communities Council Directive 2010/63/EU and with local laws and regulations. A statement confirming that the study has been reviewed and approved by an ethical or advisory board should also be included (http://www.eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32010L0063).
Data Sharing and Accessibility
The journal encourages authors to share the data and other artifacts supporting the results in the paper by archiving it in an appropriate public repository. Authors may include a data accessibility statement, including a link to the repository they have used, in order that this statement can be published alongside their paper.
Note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium. Once you have prepared your submission following the Guidelines, manuscripts should be submitted online at https://jag.journalagent.com/tej/?plng=eng.
Authors must declare any financial support or relationships that may pose a conflict of interest (see ‘Disclosure Statement’ above).
Two mandatory word-files prepared using Microsoft Word need to be included upon submission: A title page, the main text file that includes all parts of the text in the sequence indicated in the section 'Parts of the manuscript', including figure legends but the tables and figures should be supplied separately. The main text file should be prepared using Microsoft Word, double-spaced and should not contain author name(s), affiliation(s) or information(s) regarding their identity to ensure blind review.
Each figure should be supplied as a separate file, with the figure number incorporated in the file name. For submission, figures with 300 d.p.i. saved as .jpg or .bmp files should be uploaded.
The submission system will prompt you to use an ORCiD (a unique author identifier) to help distinguish your work from that of other researchers.
An optional cover letter may be included; the text can be entered directly into the field “Message to the Editor” or uploaded as a separate file.
Authors who are willing to submit their manuscripts to TEJ are required to complete and sign the Copyright Transfer Form. Please send these forms electronically when submitting your manuscript. Article evaluation process cannot be started until all documents are received.
4. Manuscript Categories and Requirements
Original Research - reports of new research findings or conceptual analyses that make a significant contribution to the current knowledge (3500 word limit). The relevant checklist must be provided in the submission documents.
Literature Reviews - Critical reviews of the literature (narrative or scoping) should provide meaningful and scientific contributions from the experts on the specific topic (5000 word limit). Should avoid excessive self-citations.
Case Reports / Series – reports of the diagnosis and/or the management of patient(s) with unusual observations of novel cases, diseases, therapeutic approaches with significant contribution to knowledge (3000 word limit). Case reports / series should be reported in full accordance with the PRIDE guidelines. The PRICE checklist must be provided in the submission documents.
Letters to the Editor - are welcomed (1000 word limit).
Clinical trials – Randomized controlled clinical trials should be reported in full accordance with the guidelines of PRIDE. The PRIRATE checklist must be provided in the submission documents. Following free public clinical registries can be used to register clinical trials. The registration number and project name will be published in the article.
Systematic reviews & meta analysis should comply with Transparent reporting of systematic reviews and meta-analysis (PRISMA) (6000 word limit). The PRISMA checklist must be provided in the submission documents.
When submitting manuscripts that have been written using guidelines, authors should include a statement in the beginning of “Materials and Methods” section: ‘‘This manuscript has been written according to Preferred Reporting Items for Case reports/or randomized clinical trials/or animal studies in Endodontics. A checklist for editors/referees and flowchart need to be also completed and included in the submission.
Case reports should be written to comply with the Preferred Reporting Items for Case reports in Endodontics (PRICE) 2020 guidelines. The guideline can be reached from the link http://pride-endodonticguidelines.org/price/ or from the following article Nagendrababu et al. 2020, doi : 32090342).The PRICE checklist and flowchart should be completed and included in the submission material.
Randomised clinical trials should be reported to comply with the Preferred Reporting Items for Randomized Trials in Endodontics (PRIRATE) 2020 guidelines. The guideline can be reached from the link https://pride-endodonticguidelines.org/prirate/ or from the following article (Nagendrababu et al. 2020, doi: 10.1111/iej.13294). PRIRATE 2020 checklist and flowchart should also be completed and included in the submission material. Turkish Endodontic Journal encourages authors submitting manuscripts reporting a clinical trial registration number a priori in a public clinical trial registry. The clinical registration number and the name of the trial register should be included in the beginning of “Materials and Methods” section.
Epidemiological observational trials should be written according to STrengthening the Reporting of Observational studies in Epidemiology (STROBE) guidelines. Compliance statement in the “Materials and Methods” section, STROBE checklist and flowchart should be included in the submission material. It is recommended that authors consult the following papers when writing manuscripts, which explains the rationale for the STROBE guidelines and their importance:
Diagnostic accuracy studies should be written using the Standards for Reporting of Diagnostic Accuracy Studies (STARD) 2015 guidelines. Compliance with this should be detailed in the “Materials and Methods” section. A STARD checklist (for editors/referees) and flowchart (as a Figure to be included in the manuscript for readers) should also be completed and included in the submission material. The STARD checklist and flowchart can be downloaded from: https://www.equator-network.org/reporting-guidelines/stard/
It is recommended that authors consult the following paper when writing manuscripts, which explain the rationale for the STARD guidelines and their importance:
Animal studiesshould be written using the Preferred Reporting Items for Animal Studies in Endodontology (PRIASE) 2021 guidelines. The guideline can be reached from the link https://pride-endodonticguidelines.org/priase/ or from the following article (Nagendrababu et al. 2021, doi: 10.1111/iej.13477). PRIASE 2021 checklist (for editors/referees) and flowchart (as a Figure to be included in the manuscript for readers) should also be completed and included in the submission material. Experiments on laboratory animals must comply with the Guidelines of the European Communities Council Directive 2010/63/EU and with local laws and regulations. A statement confirming that the study has been reviewed and approved by an ethical or advisory board should also be included (http://www.eur-lex.europa.eu/legal content/EN/TXT/?uri=CELEX:32010L0063).
Laboratory studies should be reported using the Preferred Reporting Items for Laboratory studies in Endodontology (PRILE) 2021 guidelines (Nagendrababu et al. 2021, doi: 10.1111/iej.13542).
When submitting manuscripts that have been written using the PRILE 2021 guidelines, authors should include the following statement in the beginning of “Materials and Methods” section: ‘‘The manuscript of this laboratory study has been written according to Preferred Reporting Items for Laboratory studies in Endodontology (PRILE) 2021 guidelines (Nagendrababu et al. 2021, doi: 10.1111/iej.13542).
A PRILE checklist (for editors/referees) and flowchart (as a Figure to be included in the manuscript for readers) should also be completed and included in the submission material.
Systematic reviews should be reported regarding their abstract and main body using the PRISMA for Abstract and PRISMA guidelines respectively (http://www.prisma-statement.org/). Authors submitting a systematic review must register the protocol in one of the readily-accessible sources/databases at the time of project inception and not retrospectively (e.g. PROSPERO database, OSF registries). The protocol registration number, name of the database or journal reference should be provided at the submission stage in the “Registration” section in the abstract and ‘Methods’ section in the main body of the text.
A PRISMA checklist and flow diagram as a Figure (to be included in the manuscript for readers) should also be included in the submission material. Source of funding (grant number, if available) should be added in the ‘Acknowledgements’ section.
Human Studies and Subjects
Manuscripts must contain a statement that all human/animal studies have been reviewed by the appropriate ethics committee providing approval number, year and committee name. If there is no human/animal subject involve, please write “Not applicable”.
All investigations on human subjects must include a statement that the subject gave informed consent. If there is no human subject involve, please write “Not applicable”.
Experimentation involving human subjects should be conducted in full accordance with the Helsinki Declaration of World Medical Association (http://www.wma.net/en/30publications/10policies/b3/index.html) and legal requirements of the country where the research had been carried out. The patient’s privacy should not be violated. Identifying information such as names, initials, hospital numbers, unnecessary details in photographs should be omitted from the submission. When detailed descriptions, photographs and/or videos of faces or identifiable body parts that might permit a patient to be identified must be included in the submission, authors must obtain written informed consent for its publication from the patient or his/her parent/guardian.
DNA Sequences and Crystallographic Structure Determinations
Manuscripts reporting protein or DNA sequences and crystallographic structure should provide Genbank or Brookhaven Protein Data Bank accession numbers, respectively.
5. Manuscript preparation
Authors should write their manuscripts in US English. Spelling and phrasing should conform to standard usage and be consistent throughout the paper. Authors whose native language is not English are encouraged to consult with a native speaker or to collaborate with a colleague whose English skills are more advanced. Authors may also use professional translation services at their own expense. Please note that using language editing services does not imply that the article will be selected for peer-review or be accepted by TEJ.
Accepted manuscripts are copy-edited for grammar, punctuation, format, and clarity. Artificial intelligence technology is partially used in the English language correction of articles. A PDF proof of the manuscript is sent to the corresponding author and their publication approval is requested within 2 days of receipt of the proof.
Style and format
Use A4 page format in Microsoft Word software, normal margins (top & bottom & left & right 2.5 cm), Times New Roman Font, Font size 12, double line spacing for main text and single line spacing for “References” section. US English grammar check option should be enabled. Words and abbreviations in Latin should be written in italics: “et al., in vivo, in vitro, in utero, in situ, ad libitum, clostridium perfringens, Staphylococcus aureus”.
Abbreviations used for units, prefixes, and symbols should comply with the International System of Units (SI) (http://physics.nist.gov/Pubs/SP330/sp330.pdf). If this is not possible, SI equivalents must be presented between parentheses. The complete names of individual teeth must be given in the main text (e.g., maxillary right central incisor). FDI 2-digit system should be used in table and figure legends (e.g., 11 for maxillary right central incisor).
Abbreviations should be used sparingly – only where they ease the reader’s task by reducing repetition of long, technical terms. Initially, use the word in full, followed by the abbreviation in parentheses. After that, use the abbreviation only.
Chemical substances should be referred to by the generic name only. Trade names should not be used. Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name, and the manufacturer’s name and location in parentheses.
Parts of the Manuscript
The manuscript should be submitted in separate files: (A) Title page; (B) Main text file; (C) Figures.
A. Title page
B. Main text file order
V. Figure Legends
Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.
Please set table format to custom borders, no vertical lines, no shades, no background colors. Tables should be numbered consecutively with Arabic numerals in the order mentioned in the text.
All tables must be included in the main text of the article followed by figure legends in separate pages. All tables should be self-explanatory. Please provide full explanation for abbreviations even if they are presented in the main text. Legends should be written in Times New Roman and be positioned right above the table.
6. Publication Process after Acceptance
If your paper is accepted, the author identified as the formal corresponding author will receive an email prompting them to log in to Author Services and they will be required to complete a copyright license agreement on behalf of all authors of the paper.
Once the paper has been typeset, the corresponding author will receive an email alert containing proof to be checked and corrected before publication within seven days. It is, therefore, essential that a working email address is provided for the corresponding author. Proofs should be corrected carefully; responsibility for detecting errors lies with the author.
Articles will generally appear in the order in which they were accepted as publication; however, Editor-in-Chief and Editorial Board reserve the right to modify this schedule in the presence of critical scientific issues.
Digital Object Identifier (DOI) number is a unique alphanumeric identifier assigned by a registration agency. Once it is assigned to an article, the DOI will never change; therefore, it is ideal for citing and linking electronic documents. Your article will be assigned a DOI number provided by the CrossRef registration agency.
Correction, Retraction & Removal
A formal correction will be issued in the journal by the Editor-in-Chief if only a small portion of otherwise reliable article is flawed in a way that does not severely affect the findings reported in it (such as mistakes in the spelling of a drug, miscalculation of a formula, mismatch between images and their captions or incorrect author list). Online articles will not be corrected directly. An erratum (for publishing error) or a corrigendum (for author error) will be published in the next issue of the journal.
Articles may be retracted by its authors or by the Editor-in-Chief under the advice of the scientific community. If authors are willing to retract an article before publication(accepted or under review), requests must be sent to the Editor-in-Chief from the corresponding author of the manuscript. This document must include the reason the article should be retracted and written confirmation (email, fax, letter) from all authors that they agree on the retraction. A formal retraction announcement written by the Editor-in-Chief will be published.
Please contact editorial office by sending an email to: [email protected]
Address: Mevlanakapı Mah. Turgüt Özal Cad. Kemikliburun Sok. Nesrin Apt. No: 1A, Şehremini, İstanbul
Tel: +90 212 621 34 49
Fax: +90 212 621 34 50
Publisher: KARE PUBLISHING
Tel: +90 216 550 61 11
Fax: +90 216 550 61 12
E-mail: [email protected]